{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
aminosalicylic acid
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Pelretin is an antikeratinizing agent that was in phase II trials for the treatment of skin disorders. However, these studies were discontinued. In addition, pelretin was studied in cosmetic as a cream to treat acne and against skin wrinkling. Information about the further development of pelretin is not available.
Status:
Investigational
Source:
NCT01239069: Phase 2 Interventional Completed Dry Eye
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tomicorat is an anti-inflammatory agent.
Status:
Investigational
Source:
NCT00741442: Phase 2 Interventional Completed Hyperuricemia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
USAN:METHYL PALMOXIRATE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Methyl palmoxirate, an oral hypoglycemic agent, was studied as a selective and irreversible inhibitor of the mitochondrial enzyme carnitine palmitoyltransferase and of long-chain fatty acid oxidation to treat diabetes. In addition, this compound was used to study the brain lipid metabolism by quantitative autoradiography or positron emission tomography (PET).
Class (Stereo):
CHEMICAL (MIXED)
Enisoprost is a prostaglandin E1 analog. Enisoprost exerts immunosuppressive activity and gastric antisecretory effect. Enisoprost was being studied for the treatment of peptic ulcer and transplant rejection. Enisoprost development has been discontinued.
Class (Stereo):
CHEMICAL (RACEMIC)
Suriclone is a dithiinopyrrole derivative patented by Rhone-Poulenc S. A. as a sedative and anxiolytic drug. The mechanism of action by which suriclone produces it's sedative and anxiolytic effects is by modulating GABAA receptors, although suriclone is more subtype-selective than most benzodiazepines. In clinical trials, Suriclone shows a significant anxiolytic effect. The most common adverse reaction was dizziness.
Status:
Investigational
Source:
NCT03592472: Phase 3 Interventional Recruiting Renal Cell Carcinoma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Abexinostat (PCI-24781) is a novel, second-generation phenyl hydroxamic acid–based, orally bioavailable HDAC inhibitor that has previously been shown to have activity in vitro and in vivo against a broad array of cancers, including hematopoietic malignancies and bone and soft-tissue sarcomas. Abexinostat is a pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM, modest potent to HDACs 2, 3, 6, and 10 and greater than 40-fold selectivity against HDAC8. Abexinostat exhibits potent antitumor activity against a variety of tumor cell lines with GI50 ranging from 0.15 uM to 3.09 uM. PCI-24781 also has an antiproliferative effect on HUVEC endothelial cells with GI50 of 0.43 uM. Abexinostat treatment causes dose-dependent accumulation of both acetylated histones and acetylated tubulin in HCT116 or DLD-1 cells, induces expression of p21, and leads to PARP cleavage and accumulation of the γH2AX. It has also shown good tolerability and activity in Phase I and II clinical trials against lymphoma, as well as against solid tumors in Phase-I trials. Additionally, it acts as a potent radiosensitizing agent and is synergistic with cytotoxic chemotherapy, such as doxorubicin in preclinical models.
Status:
Investigational
Source:
NCT01041677: Phase 2 Interventional Completed Obesity
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Johnson and Johnson was developing usistapide, a microsomal triglyceride transfer protein (MTTP) inhibitor, for the treatment of obesity and type 2 diabetes. Usistapide, also known as JNJ-16269110 and R256918, has been used in trials studying the treatment of obesity, overweight, metabolic diseases, nutrition disorders, and nutritional and metabolic diseases. Usistapide was removed from the company pipeline and appears to have been discontinued.
Status:
Investigational
Source:
NCT01452919: Phase 3 Interventional Completed Schizophrenia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
LY404039 [(-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid] is an agonist of orthosteric metabotropic glutamate receptor (mGluR)2/3. In addition, it acts as an agonist at dopamine D2 receptors. LY404039 demonstrated broad antipsychotic and anxiolytic efficacy across multiple animal models. LY-2140023 is a methionine amide prodrug of LY-404039 being developed by Eli Lilly & Co for the potential oral treatment of schizophrenia.
Status:
Investigational
Source:
NCT03198663: Not Applicable Interventional Completed HIV/AIDS and Infections
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
